Pfizer Inc. Stock
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pfizer Inc. | 1.400% | -0.751% | 9.877% | -25.891% | 1.226% | -17.127% | -25.294% |
Biogen Inc. | 2.070% | 3.184% | 2.979% | -25.234% | -12.044% | -5.210% | 5.333% |
Elanco Animal Health Inc. | 0.760% | 4.935% | 31.803% | 113.202% | 20.163% | -44.723% | - |
AbbVie Inc. | 2.510% | 2.321% | -2.783% | 14.748% | 5.739% | 59.136% | 113.982% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, the financials of Pfizer Inc. (NYSE: PFE) appear to be strong, showcasing a robust position in the pharmaceuticals industry. As a prominent player, Pfizer has consistently demonstrated growth in its total assets and revenue, laying the foundation for a favorable outlook on the company's performance. As we dive deeper into the financial statements, it becomes essential to analyze the pros and cons to acquire a comprehensive understanding of Pfizer's financial health and future potential.
*Pros: *
Growing Total Assets and Shareholders' Equity: The company's total assets have grown consistently over the past three years, from approximately €154.2 billion in 2020 to €181.5 billion in 2021, and reaching a notable USD 197.2 billion in 2022. Such growth indicates strong financial management and an increased capacity to generate income. Similarly, the total stockholder equity has also risen, reflecting the company's ability to create value for its shareholders.
Comments
News
Is Pfizer the Best Dividend Stock for You?
The pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (NYSE: PFE) benefitted a few years ago has trickled down to a small stream. As a result, share prices have fallen and
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors.
*Stock prices used were the afternoon prices of May 28, 2024. The video was published on May